CAS Number36322-90-4
Synonyms2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 4-Hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazin-3-carboxamid-1,1-dioxid; Riacen; 1,2-benzothiazine-3-carboxamide; Reudene; Zunden; Baxo; Roxiden; Larapam; Feldene; 4-hydroxy-2-méthyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxyde; Piroxicam; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Erazon; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; Artroxicam; Bruxicam; 4-Hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide; Caliment; chf1251; Im
Molecular FormulaC15H13N3O4S
Molecular Weight331.35
Purity≥98 (TLC)%
Density1.5±0.1 g/cm3
Boiling Point568.5±60.0 °C at 760 mmHg
Melting Point198-200°C
Appearancepowder
EINECS252-974-3
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 36322-90-4 |
| Catalog No. | 2A-9012051 |
| Chinese Name | 吡罗昔康 |
| Synonyms | 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 4-Hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazin-3-carboxamid-1,1-dioxid; Riacen; 1,2-benzothiazine-3-carboxamide; Reudene; Zunden; Baxo; Roxiden; Larapam; Feldene; 4-hydroxy-2-méthyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxyde; Piroxicam; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Erazon; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; Artroxicam; Bruxicam; 4-Hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide; Caliment; chf1251; Im |
| Molecular Formula | C15H13N3O4S |
| Molecular Weight | 331.35 |
| Purity | ≥98 (TLC) |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 568.5±60.0 °C at 760 mmHg |
| Melting Point | 198-200°C |
| Appearance | powder |
| Storage Condition | 2-8°C |
| Packaging | III |
| Application | Piroxicam is a nonsteroidal anti-inflammatory agent that inhibits COX activity with IC50 values of 47 and 25 μM for human monocyte COX-1 and COX-2, respectively. |
| EINECS | 252-974-3 |
| HTC | 3005101000 |
| PubChem ID | 24278641 |
| MDL Number | MFCD00057317 |
| SMILES | CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O |
| InChI | 1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20) |
| InChI Key | QYSPLQLAKJAUJT-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 41116107 |
| Hazard Symbols | 6.1(b) |
| MSDS | msds/12051_1_36322_90_4.pdf |
| Bioactivity | Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively. Related Catalog Research Areas >> Inflammation/Immunology Target COX-2:25 μM (IC50, in human monocytes) COX-1:47 μM (IC50, in human monocytes) In Vitro Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively[1]. Piroxicam (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells[3]. In Vivo Piroxicam (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration[2]. Cell Assay Urinary bladder cancer cell lines are treated with graded concentrations of carboplatin (0.05, 0.5 and 1 μM) and Piroxicam (167, 333 and 500 μM) for 72 h to assess dose-response profiles. For the combination approach, 0.05 μM of carboplatin is used with 333 μM Piroxicam. Both drugs are freshly prepared before each experiment. An untreated control group (cells not exposed to carboplatin and Piroxicam) is used for all assays[3]. Animal Admin Dogs[2] Dogs undergo tumor staging, including thoracic and abdominal radiography, cystography, ultrasonography, and cystoscopy (with collection of tissue samples) before treatment and after 4 weeks of Piroxicam (0.3 mg/kg qd 24-h p. o.) treatment. Dogs receive no other cancer treatment during the 4 weeks of Piroxicam treatment. Tissue samples are immediately frozen in liquid nitrogen for PGE2 analysis or fixed in 10% neutral buffered formalin for immunohistochemical examination. Urine is also collected before and after Piroxicam treatment, aliquoted, and then stored at −80°C until analyzed[2]. References [1]. Kato M, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53(12):1679-85. [2]. Mohammed SI, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002 Jan 15;62(2):356-8. [3]. Silva J, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017 Apr;37(4):1737-1745. Chemical & Physical Properties Density 1.5±0.1 g/cm3 Boiling Point 568.5±60.0 °C at 760 mmHg Melting Point 198-200°C Molecular Formula C15H13N3O4S Molecular Weight 331.346 Flash Point 297.6±32.9 °C Exact Mass 331.062683 PSA 107.98000 LogP 2.23 Vapour Pressure 0.0±1.6 mmHg at 25°C Index of Refraction 1.692 InChIKey QYSPLQLAKJAUJT-UHFFFAOYSA-N SMILES CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O Storage condition 2-8°C |
| Use of | Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively. Properties Articles103 Name piroxicam Synonym More Synonyms Piroxicam Biological Activity Description Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively. Related Catalog Research Areas >> Inflammation/Immunology COX-2:25 μM (IC50, in human monocytes) COX-1:47 μM (IC50, in human monocytes) Cell Assay Urinary bladder cancer cell lines are treated with graded concentrations of carboplatin (0.05, 0.5 and 1 μM) and Piroxicam (167, 333 and 500 μM) for 72 h to assess dose-response profiles. For the combination approach, 0.05 μM of carboplatin is used with 333 μM Piroxicam. Both drugs are freshly prepared before each experiment. An untreated control group (cells not exposed to carboplatin and Piroxicam) is used for all assays[3]. References [1]. Kato M, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53(12):1679-85. [2]. Mohammed SI, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002 Jan 15;62(2):356-8. [3]. Silva J, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017 Apr;37(4):1737-1745. Chemical & Physical Properties Molecular Formula C15H13N3O4S Exact Mass 331.062683 PSA 107.98000 Index of Refraction 1.692 InChIKey QYSPLQLAKJAUJT-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 United Nations shipping name European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (Piroxicam) IMDG: TOXIC SOLID, ORGANIC, N.O.S. (Piroxicam) International air transport hazard regulations: Toxic solid, organic, n.o.s. (Piroxicam) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Perindopril erbumine | 107133-36-8 | 2A-9011938 |
| Perindoprilat | 95153-31-4 | 2A-9011939 |
| Phenytoin sodium | 630-93-3 | 2A-9011987 |
| Pioglitazone | 111025-46-8 | 2A-9012027 |
| Pioglitazone hydrochloride | 112529-15-4 | 2A-9012028 |
| Pitavastatin calcium | 147526-32-7 | 2A-9012056 |
| Poly(estradiol phosphate) | 34828-67-6 | 2A-0202304 |
| Potassium benzylpenicillin | 113-98-4 | 2A-9012085 |
| Pramipexole | 104632-26-0 | 2A-9012094 |
| Pravastatin | 81093-37-0 | 2A-9012101 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS